Results 171 to 180 of about 33,038 (222)

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg MR, Do NV, Dorff T, Fojo AT, Gaziano JM, Goryachev SD, Halabi S, Hauger RL, Nanus DM, Rebbeck TR, Pan CX, Schoen MW, Swinnerton KN, Myrie K, Ramoni RB, Fillmore NR, Paller CJ, Rettig MB.   +29 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Molecular Evolution of Castration-resistant Prostate Cancer

European Urology Focus, 2016
Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cancer. However, castration-resistant prostate cancer (CRPC) nearly invariably develops through a range of different molecular mechanisms accompanied by progression to a more aggressive phenotype.To understand the key molecular mechanisms leading to CRPC and the ...
Zoran Culig, Tapio Visakorpi, Anders Bjartell   +2 more
exaly   +3 more sources

Steroidogenesis in castration-resistant prostate cancer

Urologic Oncology: Seminars and Original Investigations, 2023
Castration resistance is in part attributable to aberrant activation of androgen receptor (AR) signaling by the intracrine activation of androgen precursors derived from adrenal glands. To overcome this, novel AR pathway inhibitors (ARPIs) that suppress androgen synthesis by CYP17 inhibition or AR activation by antiandrogen effects have been developed.
Masaki Shiota, Satoshi Endo, Leandro Blas, Naohiro Fujimoto, Masatoshi Eto   +4 more
openaire   +2 more sources

Overcoming castration resistance in prostate cancer

Current Opinion in Urology, 2012
Recent advances in our understanding of the androgen axis signaling pathway have led to the development of therapeutic strategies to overcome the state of 'castration resistance' in prostate cancer. In this review, we examine the mechanisms of castration resistance, as well as recently reported and ongoing clinical studies, which will further identify ...
Che-Kai, Tsao, Alexander C, Small, Matthew D, Galsky, William K, Oh   +3 more
openaire   +2 more sources

The hallmarks of castration-resistant prostate cancers

Cancer Treatment Reviews, 2015
Prostate cancer has become a real public health issue in industrialized countries, mainly due to patients' relapse by castration-refractory disease after androgen ablation. Castration-resistant prostate cancer is an incurable and highly aggressive terminal stage of prostate cancer, seriously jeopardizing the patient's quality of life and lifespan.
Maria, Katsogiannou, Hajer, Ziouziou, Sara, Karaki, Claudia, Andrieu, Marie, Henry de Villeneuve, Palma, Rocchi   +5 more
openaire   +2 more sources

Immunotherapy for Castration-Resistant Prostate Cancer

Urologic Clinics of North America, 2012
The improved survival with sipuleucel-T, an autologous antigen-presenting cell-based agent, for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer supports immunotherapy as a valid approach. Also, multiple novel immunotherapeutic approaches are undergoing vigorous investigation.
Guru, Sonpavde, Philip W, Kantoff
openaire   +2 more sources

Castration-Resistant Prostate Cancer

Urologic Clinics of North America, 2017
Men with advanced prostate cancer are typically treated with hormonal therapy, which results in tumor shrinkage. However, tumors relapse and develop into a highly aggressive and lethal form of the disease, termed castration-resistant prostate cancer (CRPC).
Kelly Stratton, Michael Cookson
openaire   +2 more sources

New developments in castrate‐resistant prostate cancer

BJU International, 2012
Castrate‐resistant prostate cancer (CRPC) occurs when disease progresses in the presence of castrate levels of androgens and remains sensitive to further hormonal manipulation. For many years the treatment of CRPC was limited to the use of docetaxel for metastatic disease.
Shore, N., Mason, M., de Reijke, Th M.
openaire   +2 more sources